0001209191-16-156690.txt : 20161223 0001209191-16-156690.hdr.sgml : 20161223 20161223171116 ACCESSION NUMBER: 0001209191-16-156690 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161223 FILED AS OF DATE: 20161223 DATE AS OF CHANGE: 20161223 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS INC CENTRAL INDEX KEY: 0001175505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260038620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-365-5600 MAIL ADDRESS: STREET 1: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Williams Lewis T CENTRAL INDEX KEY: 0001475714 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36070 FILM NUMBER: 162069379 MAIL ADDRESS: STREET 1: C/O FIVE PRIME THERAPEUTICS, INC. STREET 2: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-12-23 0 0001175505 FIVE PRIME THERAPEUTICS INC FPRX 0001475714 Williams Lewis T TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President, CEO and Chairman Common Stock 2016-12-23 4 M 0 155 4.56 A 434047 D Common Stock 2016-12-23 4 M 0 19 6.89 A 434066 D Common Stock 2016-12-23 4 M 0 10 8.49 A 434076 D Common Stock 2016-12-23 4 M 0 29816 5.54 A 463892 D Common Stock 2016-12-23 4 S 0 29700 50.49 D 434192 D Common Stock 2016-12-23 4 S 0 300 51.02 D 433892 D Employee Stock Option (right to buy) 4.56 2016-12-23 4 M 0 155 0.00 D 2019-04-15 Common Stock 155 91217 D Employee Stock Option (right to buy) 6.89 2016-12-23 4 M 0 19 0.00 D 2020-07-28 Common Stock 19 14438 D Employee Stock Option (right to buy) 8.49 2016-12-23 4 M 0 10 0.00 D 2021-10-19 Common Stock 10 16349 D Employee Stock Option (right to buy) 5.54 2016-12-23 4 M 0 29816 0.00 D 2022-07-15 Common Stock 29816 31159 D The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2016. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.94, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.04, inclusive. This option is fully vested and immediately exercisable. /s/ Francis Sarena, Attorney-in-fact 2016-12-23